Pleurodynia Treatment Market Size to USD 24.61 Mn, Growing Prevalence of Viral Infections to Boost Market Growth - Technavio

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- The "Pleurodynia Treatment Market by Therapy and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years.

The potential growth difference for the pleurodynia treatment market size between 2021 and 2026 is USD 24.61 million. To get the exact yearly growth variance and the Y-O-Y growth rate, Request a FREE PDF Sample Report.

• Market Driver: The growing prevalence of viral infections is driving the market growth. Older children and adults are more prone to pleurodynia. Major etiologic agents in epidemic pleurodynia are viruses Coxsackie B3 and B5. According to a cohort study of COVID-19-associated musculoskeletal symptoms conducted on 294 hospitalized COVID-19 patients in March 2021, 30% reported musculoskeletal complaints, and among these, 37.5% had myalgia. Countries such as China and India are hyperendemic countries for viral infections. Therefore, the increasing prevalence of pleurodynia disease will drive market growth during the forecast period.
• Market Challenge: Stringent regulatory guidelines are challenging market growth. Some of the key factors considered by regulatory bodies include efficacy, safety, pharmacological data, pharmacodynamic effects, and drug interactions. This may need additional clinical trials, which can increase the R&D expenditure for drug applicants. Such factors may limit the growth of the market in focus during the forecast period.

To learn about additional key drivers, trends, and challenges available with Technavio, View our FREE Sample Report!

The pleurodynia treatment market report is segmented by therapy (painkillers and immunoglobulin) and geography (North America, Europe, Asia, and Rest of World (ROW)).

By therapy, the painkillers segment will be a significant contributor to market growth during the forecast period. There is no specific treatment for pleurodynia. However, non-steroidal anti-inflammatory drugs (NSAIDs) for pain and pleurisy or blockage of peripheral nerves, with 1% lidocaine (Xylocaine) infusion, are prescribed for patients. Thus, the adoption of painkillers to relieve the pain caused by pleurodynia due to infection by Coxsackie A and Coxsackie B viruses drives the growth of this segment.

Get lifetime access to our Technavio Insights! Subscribe to our Basic Plan billed annually at USD 5000

By geography, North America will be the leading region with 40% of the market's growth during the forecast period. The US and Canada are the key countries for the pleurodynia treatment market in North America. The growing research on antiviral drugs, the increasing healthcare expenditure in the region, and the presence of key vendors will drive the pleurodynia treatment market growth in North America during the forecast period. Moreover, market growth in this region will be faster than the growth of the market in Rest of World (ROW).

Find additional insights into the contribution of all the segments and regional opportunities in the report. Buy Now for detailed segment information

• Abbott Laboratories
• GlaxoSmithKline Plc
• Hudson Pharma
• Johnson and Johnson
• Merck and Co. Inc.
• Novartis AG
• Opsonin Pharma Ltd.
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Sanofi

Want your report customized? Speak to an analyst and personalize your report according to your needs

Lennox-Gastaut Syndrome Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The rising population with risk factors for LGS is driving market growth. The main risk factors for LGS include stroke, cortical dysplasia, perinatal hypoxia, trauma, and tuberous sclerosis. The number of patients with these medical conditions is increasing.

Myopia and Presbyopia Treatment Market by Type and Geography - Forecast and Analysis 2022-2026: The increasing prevalence of myopia and presbyopia is driving market growth. The prevalence of refractive errors such as myopia and presbyopia is increasing significantly across the world. Myopia has also been shown to increase the risk of vision-threatening complications such as glaucoma, cataract, and retinal detachment.

Browse Health Care Market Reports

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Therapy
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between 2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Therapy

• 5.1 Market segments 
• Exhibit 24: Chart on Therapy - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Therapy - Market share 2021-2026 (%)

• 5.2 Comparison by Therapy 
• Exhibit 26: Chart on Comparison by Therapy
• Exhibit 27: Data Table on Comparison by Therapy

• 5.3 Painkillers - Market size and forecast 2021-2026
• Exhibit 28: Chart on Painkillers - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Painkillers - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Painkillers - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Painkillers - Year-over-year growth 2021-2026 (%)

• 5.4 Immunoglobulin - Market size and forecast 2021-2026
• Exhibit 32: Chart on Immunoglobulin - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Immunoglobulin - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Immunoglobulin - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Immunoglobulin - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Therapy 
• Exhibit 36: Market opportunity by Therapy ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026 
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 Canada - Market size and forecast 2021-2026
• Exhibit 62: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.9 Denmark - Market size and forecast 2021-2026
• Exhibit 66: Chart on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on Denmark - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on Denmark - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on Denmark - Year-over-year growth 2021-2026 (%)

• 7.10 China - Market size and forecast 2021-2026
• Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.11 Norway - Market size and forecast 2021-2026
• Exhibit 74: Chart on Norway - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on Norway - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on Norway - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on Norway - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 Abbott Laboratories 
• Exhibit 85: Abbott Laboratories - Overview
• Exhibit 86: Abbott Laboratories - Business segments
• Exhibit 87: Abbott Laboratories - Key news
• Exhibit 88: Abbott Laboratories - Key offerings
• Exhibit 89: Abbott Laboratories - Segment focus

• 10.4 GlaxoSmithKline Plc 
• Exhibit 90: GlaxoSmithKline Plc - Overview
• Exhibit 91: GlaxoSmithKline Plc - Business segments
• Exhibit 92: GlaxoSmithKline Plc - Key news
• Exhibit 93: GlaxoSmithKline Plc - Key offerings
• Exhibit 94: GlaxoSmithKline Plc - Segment focus

• 10.5 Hudson Pharma 
• Exhibit 95: Hudson Pharma - Overview
• Exhibit 96: Hudson Pharma - Product / Service
• Exhibit 97: Hudson Pharma - Key offerings

• 10.6 Johnson and Johnson 
• Exhibit 98: Johnson and Johnson - Overview
• Exhibit 99: Johnson and Johnson - Business segments
• Exhibit 100: Johnson and Johnson - Key news
• Exhibit 101: Johnson and Johnson - Key offerings
• Exhibit 102: Johnson and Johnson - Segment focus

• 10.7 Merck and Co. Inc. 
• Exhibit 103: Merck and Co. Inc. - Overview
• Exhibit 104: Merck and Co. Inc. - Business segments
• Exhibit 105: Merck and Co. Inc. - Key news
• Exhibit 106: Merck and Co. Inc. - Key offerings
• Exhibit 107: Merck and Co. Inc. - Segment focus

• 10.8 Novartis AG 
• Exhibit 108: Novartis AG - Overview
• Exhibit 109: Novartis AG - Business segments
• Exhibit 110: Novartis AG - Key offerings
• Exhibit 111: Novartis AG - Segment focus

• 10.9 Opsonin Pharma Ltd. 
• Exhibit 112: Opsonin Pharma Ltd. - Overview
• Exhibit 113: Opsonin Pharma Ltd. - Product / Service
• Exhibit 114: Opsonin Pharma Ltd. - Key offerings

• 10.10 Pfizer Inc. 
• Exhibit 115: Pfizer Inc. - Overview
• Exhibit 116: Pfizer Inc. - Product / Service
• Exhibit 117: Pfizer Inc. - Key news
• Exhibit 118: Pfizer Inc. - Key offerings

• 10.11 Reckitt Benckiser Group PLC 
• Exhibit 119: Reckitt Benckiser Group PLC - Overview
• Exhibit 120: Reckitt Benckiser Group PLC - Business segments
• Exhibit 121: Reckitt Benckiser Group PLC - Key offerings
• Exhibit 122: Reckitt Benckiser Group PLC - Segment focus

• 10.12 Sanofi 
• Exhibit 123: Sanofi - Overview
• Exhibit 124: Sanofi - Business segments
• Exhibit 125: Sanofi - Key news
• Exhibit 126: Sanofi - Key offerings
• Exhibit 127: Sanofi - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 128: Inclusions checklist
• Exhibit 129: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 130: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 131: Research methodology
• Exhibit 132: Validation techniques employed for market sizing
• Exhibit 133: Information sources

• 11.5 List of abbreviations 
• Exhibit 134: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

SOURCE Technavio